Last edition
News about "SK Bioscience"
SK bioscience Files IND for Global Phase 3 Trial of Two-Dose Varicella Vaccine
SK bioscience's Phase 3 clinical trial of SKYVaricella aims to evaluate the immunogenicity and safety of the 2-shot varicella vaccine in roughly 800 children aged 12 months to 12 years, with completion targeted by 2027.
SK Bioscience | 02/09/2025 | By Dineshwori
SK bioscience Submits IND Application for Phase 1/2 Trial of Adjuvanted Influenza Vaccine Candidate
SK bioscience has submitted an Investigational New Drug (IND) application to South Korea’s Ministry of Food and Drug Safety for Phase 1/2 clinical trials of its adjuvanted influenza vaccine candidate, NBP607B, aimed at boosting protection for older adults.
SK Bioscience | 19/07/2025 | By Mrinmoy Dey | 132
SK bioscience to Establish a Vaccine-Biopharma Hub
The R&PD center will be a 30,413.8 sq mt site in Songdo, Republic of Korea
SK Bioscience | 13/02/2023 | By Sudeep Soparkar | 552
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy